Business Context and Reporting Period
Company: Calidi Biotherapeutics, Inc. (CLDI)
Filing Type: Form 8-K (Current Report)
Date of Report: November 14, 2024
Event: Entry into a Material Definitive Agreement for a public equity offering.
Key Financial Metrics and Transaction Details
- Offering Size: 4,437,869 shares of Common Stock.
- Offering Price: $1.69 per share.
- Gross Proceeds: Approximately $7.5 million (before fees and expenses).
- Placement Agent Fees: 8.0% cash fee plus 1% management fee of gross proceeds.
- Placement Agent Warrants: 221,893 warrants issued (5% of shares sold) at an exercise price of $2.1125 (125% of offering price).
- Warrant Terms: Exercisable 6 months post-issuance; expire 5 years after the initial exercise date.
Material Changes and Agreements
The Company entered into a Placement Agency Agreement with Ladenburg Thalmann & Co. Inc. on November 14, 2024, with the offering closing on November 15, 2024. Key contractual restrictions include:
- Market Stand-Off: The Company is restricted from issuing additional Common Stock or equivalents for 15 days post-closing and from entering variable rate transactions for 6 months.
- Lock-Up Agreements:
- Company: 15-day lock-up period.
- Directors and Executive Officers: 90-day lock-up period.
- Exception: The CEO may sell up to 10,000 shares for tax planning purposes after 25 days.
Outlook, Risks, and Unusual Items
Use of Proceeds: The filing does not explicitly state the specific allocation of the $7.5 million in gross proceeds, though it notes the funds are net of placement agent fees and offering expenses.
Regulatory Status: The Placement Agent Warrants were sold unregistered under Section 4(a)(2) of the Securities Act and Regulation D.
Emerging Growth Company: The Company is classified as an emerging growth company.
Investor Verification Checklist
- Verify the net proceeds after deducting the 9% total fee structure (8% cash + 1% management) and other offering expenses.
- Confirm the dilution impact of the 221,893 Placement Agent Warrants exercisable at $2.1125.
- Review the specific use of proceeds in the accompanying press releases (Exhibits 99.1, 99.2, 99.3) as the 8-K text does not detail operational funding plans.
- Monitor the 15-day market stand-off period ending mid-November 2024 for potential follow-on issuances.